SLQT Q1 FY27 earnings call: key takeaways

• SLQT reported revenue of $280 million for Q1, which was 15% lower than a year ago, but adjusted EBITDA improved to a loss of $17 million (22:32)
• The company highlighted efficiency gains and technology investments as key drivers of profitability. (16:44)

Results vs expectations

What changed since last quarter

• The company raised its focus on profitability over growth due to market conditions. (15:04)
• SLQT expects to maintain a smaller agent force but with higher productivity. (32:48)
• The CFO mentioned plans to seek approval for a reverse stock split to remain listed on the NYSE. (23:49)

What analysts pressed on

• Whether the Inflation Reduction Act will continue to pressure healthcare services revenue. (48:00)
• How the company plans to manage the impact of IRA drugs on top-line revenue. (48:00)
• Concerns about the potential for increased marketing spend by carriers affecting costs. (46:35)

In their words

• We are pleased with the customer engagement we are seeing early in AUP (23:49)
• Our agent-led model will again produce results that benefit policyholders, carrier partners, and our investors (15:04)
• The impact on EBITDA and profitability was far less significant given our lower drug prices were largely offset by manufacturer reimbursements Ryan Clement (22:32)
• We are excited about the season ahead and look forward to updating investors (31:58)